Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer.
Min ShiHong YuanJun JiShouwei ZhangQingyuan LiYawei ChenXiaoli GongZhenggang ZhuJun ZhangPublished in: Therapeutic advances in medical oncology (2022)
This prospective and serial genomic profiling study revealed the utility of ctDNA in predicting clinical outcomes in mCRC patients under first-line treatment. Levels of KRAS MMB might aid in monitoring therapeutic efficacy in mCRC patients at pretreatment/after four cycles of first-line treatment.